Tag: EP

CAPA Investigation for Unimplemented Pharmacopoeial Changes During Submission Support In the pharmaceutical manufacturing landscape, compliance with pharmacopoeial standards is crucial to ensure the quality and safety of products. A failure…

Addressing the Risks of Non-Compliance with Pharmacopoeial Changes During Supplier Qualification In today’s intricate pharmaceutical landscape, ensuring compliance with updated pharmacopoeial standards is crucial for maintaining quality and safety in…

Addressing Unjustified In-House Specifications During Audit Reviews to Prevent Recurrence The pharmaceutical industry often faces challenges related to compliance and quality assurance, particularly when it comes to in-house specifications for…

Creating an Inspection-Ready Strategy for Test Method Non-Compliance in Audits In the world of pharmaceutical manufacturing, test method non-compliance during audit reviews poses significant challenges to quality assurance and regulatory…

Misapplication of Reference Standards During Inspection: Developing a CAPA for Compendial Failures The use of reference standards is a critical aspect of pharmaceutical quality control and compliance. However, instances of…

Risks of Using Outdated Pharmacopoeial Monographs During Supplier Qualification In pharmaceutical manufacturing, ensuring the quality and compliance of raw materials is a paramount concern. A common problem that organizations face…

Addressing Non-Compliance in Test Methods During Submission Support In the realm of pharmaceutical manufacturing, adherence to established test methods is non-negotiable. Non-compliance to these methods during submission support can jeopardize…

Addressing In-House Specification Issues During Inspections: A Comprehensive Investigation In pharmaceutical manufacturing, adherence to specifications is paramount; however, challenges arise when unjustified in-house specifications come into play during inspections. This…

Addressing In-House Specification Challenges During Inspections: A CAPA Approach for Compendial Failures During regulatory inspections, the presence of unjustified in-house specifications can result in significant compliance risks, particularly concerning the…

Understanding and Addressing Test Method Non-Compliance Observations During Audit Reviews In the highly regulated pharmaceutical industry, maintaining stringent compliance with test methods is paramount. A non-compliance incident during an audit…

Analyzing Unjustified In-House Specifications During Submission Support: A Compliance Investigation In the dynamic landscape of pharmaceutical manufacturing, maintaining compliance with various pharmacopoeial standards such as USP, EP, and IP is…

Implementing Pharmacopoeial Changes During Supplier Qualification to Prevent Repeated Issues Sourcing raw materials, including active pharmaceutical ingredients (APIs) and excipients, from suppliers requires stringent adherence to pharmacopoeial standards. Yet, failures…